Profile data is unavailable for this security.
About the company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
- Revenue in USD (TTM)0.00
- Net income in USD-168.09m
- Incorporated2007
- Employees142.00
- LocationKura Oncology Inc12730 HIGH BLUFF DRIVE, SUITE 400SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 500-8800
- Fax+1 (302) 655-5049
- Websitehttps://www.kuraoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Soleno Therapeutics Inc | 0.00 | -52.03m | 1.47bn | 33.00 | -- | 9.86 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.49bn | 267.00 | -- | 9.85 | -- | 9.34 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Dynavax Technologies Corp | 236.15m | 9.22m | 1.51bn | 408.00 | 231.23 | 2.44 | 110.55 | 6.40 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.52bn | 20.00 | -- | 15.43 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.52bn | 154.00 | -- | 19.38 | -- | 27.56 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Arcus Biosciences Inc | 237.00m | -231.00m | 1.54bn | 577.00 | -- | 2.18 | -- | 6.51 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Neumora Therapeutics Inc | 0.00 | -254.02m | 1.56bn | 120.00 | -- | 3.67 | -- | -- | -1.55 | -1.55 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Kura Oncology Inc | 0.00 | -168.09m | 1.59bn | 142.00 | -- | 3.14 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.59bn | 284.00 | -- | -- | -- | 38.15 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Spyre Therapeutics Inc | 688.00k | -364.23m | 1.60bn | 30.00 | -- | -- | -- | 2,325.80 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Taro Pharmaceutical Industries Ltd | 629.18m | 53.87m | 1.61bn | 1.55k | 29.81 | 0.8958 | 18.90 | 2.55 | 1.43 | 1.43 | 16.74 | 47.70 | 0.2928 | 1.50 | 3.31 | -- | 2.51 | -0.166 | 3.03 | -0.2023 | 48.47 | 52.85 | 8.56 | -0.6294 | 3.04 | -- | 0.00 | -- | 9.81 | -1.25 | 111.70 | -28.17 | 12.06 | -- |
Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.64bn | 92.00 | -- | 3.05 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.65bn | 246.00 | 12.54 | 3.20 | 10.18 | 2.67 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Akero Therapeutics Inc | 0.00 | -179.27m | 1.66bn | 58.00 | -- | 1.96 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 31 Mar 2024 | 7.07m | 9.28% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 5.81m | 7.62% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 5.67m | 7.44% |
BVF Partners LPas of 31 Mar 2024 | 4.79m | 6.28% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.20m | 5.51% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.96m | 5.20% |
Paradigm BioCapital Advisors LPas of 22 Apr 2024 | 3.86m | 5.07% |
Avoro Capital Advisor LLCas of 31 Mar 2024 | 3.85m | 5.05% |
Holocene Advisors, LPas of 31 Mar 2024 | 2.44m | 3.20% |
Armistice Capital LLCas of 31 Mar 2024 | 2.05m | 2.69% |